drugset / Trial / NCT01405651
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of ONO-6950 across ascending multiple doses in healthy adult male and female subjects. The secondary objectives are to characterize the PK and pharmacodynamic (PD) profiles of ONO-6950 by measuring plasma concentrations of ONO-6950 and pulmonary function.
Timeline
- Start
- 2011-07
- Primary completion
- 2011-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GEMILUKAST | Small molecule | 30 mg | — |
| Comparator | GEMILUKAST | Small molecule | 100 mg | — |
| Comparator | GEMILUKAST | Small molecule | 300 mg | — |
Indications
No indication recorded.